GSK (NYSE:GSK) Stock Crosses Above 200 Day Moving Average – Time to Sell?

GSK PLC Sponsored ADR (NYSE:GSK) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $43.95 and traded as high as $50.57. GSK shares last traded at $50.3550, with a volume of 4,220,452 shares changing hands.

Analyst Ratings Changes

GSK has been the subject of a number of research reports. HSBC reiterated a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Barclays cut GSK from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 6th. Cfra set a $53.00 price target on shares of GSK in a report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of GSK in a research report on Monday, December 29th. Finally, Morgan Stanley reissued an “underweight” rating on shares of GSK in a research report on Wednesday, January 14th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $44.13.

GSK Price Performance

The stock has a fifty day moving average of $48.69 and a two-hundred day moving average of $43.95. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $102.64 billion, a price-to-earnings ratio of 14.22, a PEG ratio of 1.45 and a beta of 0.45.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The company had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. During the same quarter in the prior year, the business earned $0.50 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 8th. Shareholders of record on Friday, November 14th were given a $0.4171 dividend. This represents a $1.67 annualized dividend and a yield of 3.3%. The ex-dividend date was Friday, November 14th. GSK’s dividend payout ratio (DPR) is presently 48.02%.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk bought 1,470,000 shares of GSK stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the transaction, the insider owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GSK. Twin Peaks Wealth Advisors LLC bought a new stake in GSK in the 2nd quarter valued at about $25,000. CNB Bank acquired a new stake in shares of GSK in the third quarter valued at approximately $31,000. SOA Wealth Advisors LLC. raised its holdings in shares of GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 605 shares during the last quarter. CoreFirst Bank & Trust bought a new stake in shares of GSK during the second quarter valued at approximately $33,000. Finally, MTM Investment Management LLC acquired a new position in shares of GSK during the second quarter worth approximately $37,000. Institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.